47 results about "Movement disorders" patented technology

Disclosed are a dual regulator for mGluR5 and HDAC6 and use thereof. More specifically, disclosed are a compound that simultaneously regulates mGluR5 and HDAC6, and use thereof as a therapeutic agent for movement disorders.

Provided herein are 19-nor C3, 3-disubstituted steroids of Formula (I); and pharmaceutically acceptable salts thereof; wherein R1, R2, R3, and R4 are as defined herein, and A is a heteroaryl ring system comprising 3 or 4 nitrogens as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, and tinnitus.

Treatments of neuromuscular conditions, activity-induced muscle damage, metabolic myopathies, and movement disorders with compositions comprising 2-((5-fluoropyridin-3-yl)methyl)-6-(2-(2,2,2-trifluoroethoxy)pyrimidin-5-yl)pyridazin-3(2H)-one (Compound 1), as well as solid forms of Compound 1, and pharmaceutical compositions of Compound 1, and kits of Compound 1, are described herein.

Devices, systems, and techniques for monitoring patient movements using remote sensors are described herein. For example, processing circuitry may be configured to control a user interface of a mobile computing device to deliver a notification to a user to perform at least one movement test and receive, via the user interface, user input requesting to begin the at least one movement test. Responsive to receiving the user input, the processing circuitry can control the user interface to display a set of instructions for the at least one movement test during a period of time, control a camera of the mobile computing device to generate image data of the patient corresponding to the at least one movement test during the period of time, and determine, based on the image data, one or more metrics corresponding to the at least one movement test.

Provided herein are 19-nor C3, 3-disubstituted steroids of Formula (I); and pharmaceutically acceptable salts thereof; wherein R1, R2, R3, and R4 are as defined herein, and A is a heteroaryl ring system comprising 3 or 4 nitrogens as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, and tinnitus.

The present disclosure provides a crystalline form of enantiopure deuterium-enriched bupropion, pharmaceutical compositions, and methods of treating mood disorders, neurological disorders, movement disorders, cardiovascular disorders, metabolic disorders, and other disorders using a crystalline form of enantiopure deuterium-enriched bupropion.

A method of treating movement disorders, by administering an effective amount of a psychedelic to an individual having a movement disorder, and treating the movement disorder.

The present invention provides therapeutic methods, pharmaceutical compositions and unit dose formulations for the treatment of dyskinesia, such as the treatment of muscular dyskinesia using a muscarinic acetylcholine receptor inhibitor in combination with a muscarinic acetylcholine receptor activator.

Provided herein are osmotic dosage forms containing deutetrabenazine for use in the treatment of, e.g., hyperkinetic movement disorders. When orally administered to a subject on a once-daily basis, the dosage forms provide a favorable pharmacokinetic profile for the active agent indicating treatment efficacy over an extended period of time.

The invention provides a limb dyskinesia recognition and active exercise auxiliary control method based on computer vision, and relates to the technical field of exercise rehabilitation engineering. According to the method, the motion image sequence of the upper limbs and / or the lower limbs of the patient is obtained, the multi-joint three-dimensional coordinates are extracted to form the spatial position data, and the joint angles and the angular speeds are calculated to obtain the joint motion state data. Combining with the torque support evidence, identifying joint angle deviation, angular velocity abnormity and compensation behaviors, generating a dyskinesia identification result containing intention intensity and compensation indexes, and determining target auxiliary joint and auxiliary torque output according to the dyskinesia identification result; and active motion auxiliary control is implemented in modes of joint driving assistance, torque compensation, track amplification or lateral force compensation and the like. According to the invention, fine recognition and self-adaptive assistance of dyskinesia can be realized without additional wearable equipment, and the accuracy and safety of rehabilitation training are improved.

This invention discloses a method for Chinese character input combining eye-tracking and P300 technology. The method utilizes the spatial modulation information of the eye-tracking device to select a mode: the eye-tracking device collects the user's visual trajectory in real time, obtaining the coordinates of the user's eye movement points. When the user gazes at the start option, the system detects this intention and generates a command to activate the spelling process. Combining the eye-tracking device and P300 technology, the initials and finals of the Chinese characters are selected. The method then integrates with a Pinyin input method to achieve the function of inputting Chinese characters: after selecting the initials and finals, the user switches to the Pinyin input method, selects the target Chinese character, and thus achieves the Chinese character input function. This invention, combining eye-tracking and P300 technology for Chinese character input, allows users to achieve computer typing functions without taking any action, relying solely on their eyes and brain. Furthermore, the use of a standard Chinese input method's character library enables matching Chinese characters after spelling. This expands the scope of assistive devices for people with movement disorders beyond computer devices themselves, and has significant practical implications.

The invention provides therapeutic methods, pharmaceutical compositions, and unit dose formulations for treating movement disorders, such as using a muscarinic acetylcholine receptor inhibitor in combination with a muscarinic acetylcholine receptor activator to treat the movement disorder, such as dystonia. In some aspects, the invention provides a method of treating a movement disorder in a patient, where the method comprises administering to a patient in need thereof (i) a muscarinic acetylcholine receptor inhibitor in an amount effective to treat the movement disorder and (ii) a muscarinic acetylcholine receptor activator in an amount effective to reduce the frequency and / or magnitude of at least one side effect of the muscarinic acetylcholine receptor inhibitor, to thereby treat the movement disorder.

The invention discloses guideRNA (Ribonucleic Acid) of a targeted mouse Gba gene, the guideRNA is designed according to the eleventh exon of a mouse Gba-202 transcript, and the nucleotide sequence of the guideRNA is as shown in SEQ ID No. 1. The invention also discloses a construction method of the Parkinson's mouse model and application of the construction method in research on pathogenesis of primary Parkinson's disease. The invention provides an innovative and reliable construction method of the Parkinson's mouse model through the combined action of a PD risk gene Gba mutant mouse and a high milk diet dangerous environment, and the constructed Parkinson's mouse model can better simulate the occurrence and development process of PD, conforms to the pathological progress of PD progressive aggravation, can monitor the early change of PD, and has a good application prospect. And the model can dynamically quantify the dyskinesia and pathological progress of the PD, and can provide a research basis for different stages of PD.

Disclosed herein are new dosage regimens for deuterium-substituted benzoquinoline compounds, and methods for the treatment of abnormal muscular activity, movement disorders, and related conditions.

Its simple configuration enables highly accurate and quantitative evaluation of movement disorders. [Solution] The measurement and evaluation system comprises: a detection unit that detects movements including finger movements of the user by detecting hand tracking on a head-mounted display worn by the user who is the subject of the test; a generation unit that generates a hand object, a reference point, and a target point; a display control unit that controls the display of the reference point and the target point to alternately switch in accordance with the contact of the fingertips of the hand object, and controls the display of the reference point to a fixed position from the user's viewpoint and the target point to be displayed at a different position; a measurement unit that analyzes the movements detected for each round trip and measures each measurement item of the motor impairment; and an output unit that outputs the measurement results for each measurement item.

An assistive application 10 for controlling a wearable device 12 to operate as an assistive device for alleviating symptoms of a movement disorder, stress and / or anxiety. The device has a computer pro

The utility model discloses adjustable nursing auxiliary turning-over device, the utility model relates to nursing technical field, including support frame, the inside of support frame is provided with turning-over subassembly and adjusting assembly, and turning-over subassembly includes first threaded sleeve, first slider, rotating block, support rod, turnover frame, connecting frame and limit pivot, the side of turnover frame is hinged with the inner wall of support frame, the side of rotating block is hinged with the upper end surface of first slider, and one end of support rod is hinged with the side of rotating block, the utility model has the advantages of: through screw drive mechanism with rotation motion is converted into linear motion, drives turnover frame to realize patient turning-over, and nursing personnel is not needed to manually move patient, especially applicable to the patient of big weight or the patient of limb movement disorder, through the steering of first threaded sleeve, can drive left side or right side turnover frame turnover respectively, realizes the bidirectional switching of supine and left and right lateral decubitus.

This invention discloses a system and method for treating patients with symptoms of restless legs syndrome (RLS) or periodic limb movement disorder (PLMD) using high-frequency stimulation by applying a high-frequency pulsed electrical stimulation therapeutic signal to the peroneal nerve or its branches, wherein the therapeutic signal is above the motor threshold of the muscles innervated by the peroneal nerve or its branches. Surface EMG (sEMG) responses to nerve stimulation can be used to assess a patient's response to nerve stimulation or to evaluate the efficacy of nerve stimulation, such as comparing various nerve stimulation parameter settings and selecting between these settings to achieve or balance one or more goals. The sEMG response can be obtained during muscle rest or during muscle activation.

Embodiments of the present specification provide a data processing method and system, wherein the data processing method comprises: receiving a part determination instruction submitted by a movement disorder user in a user part map for a target part region in a movement management interface; analyzing the part determination instruction, obtaining movement disorder part data associated with the target part region, and determining user data of the movement disorder user; determining at least one movement project matched with the movement disorder user in a movement project library based on the user data and the movement disorder part data, and generating a movement plan based on the at least one movement project.

A patient's visual health can be evaluated via a virtual reality (VR) system, which includes a VR headset in electronic communication with a computing device. The computing device causes virtual environments, which can include objects, to be displayed on the VR headset. Using varying combinations of eye-tracking sensors, eye-tracking cameras, motion-tracking sensors, handheld devices, and microphones, the VR headset collects data about the patient as she tracks the objects as the objects are displayed in different positions in the virtual environments. Optionally, advanced algorithms in the computing device dynamically alter the positions of the objects and analyze the patient's eye-tracking to evaluate the patient for eye movement disorders. This dynamic evaluation can facilitate a wider scope of testing and a more detailed assessment of the patient's ocular health, as compared to traditional ocular evaluation methods.

Compositions and methods for selective targeting of M1 and / or M4 muscarinic receptors, compositions and methods for treating movement disorders, such as dystonia, with improved formulations of trihexyphenidyl, and in particular, compositions comprising high chiral purity R-trihexyphenidyl or enantiomerically enriched R-trihexyphenidyl.

Dual modifiers for mGluR5 and HDAC6, and their uses are disclosed. More specifically, compounds that simultaneously antagonize both mGluR5 and HDAC6, and their use as therapeutic agents for movement disorders are disclosed.

To provide improved compositions, dosage regimens, and methods for the treatment of abnormal muscle activity, abnormal involuntary movements, and other related disorders. a) administering to the subject an initial daily dose of at least about 6 mg of deutetrabenazine per day; b) after about one week, determining the degree of control of abnormal involuntary movements achieved with the initial daily dose and the tolerability of the initial daily dose; c) increasing the daily dose of deutetrabenazine upward by 6 mg / day for subsequent daily doses if the abnormal involuntary movements are not reduced and the initial daily dose is tolerated; d) after about one week, optionally repeating steps b) and c), provided that the abnormal involuntary movements have abated and the daily dose of deutetrabenazine is tolerated; and e) decreasing the daily dose downward by at least 6 mg / day for subsequent daily doses if the subsequent dose is not tolerated. The above-mentioned problem is solved by providing deutetrabenazine or a composition containing deutetrabenazine for treating abnormal involuntary movements in a subject.

The present invention amalgamates the domains of deep brain stimulation, wearable and wireless inertial sensor systems, machine learning, and multidisciplinary design optimization to achieve an optimal parameter configuration. This present invention's respective amalgamation attains a means to automate the acquisition of an optimal parameter configuration for deep brain stimulation for movement disorders, such as essential tremor and Parkinson's disease, in a closed loop context. Wearable inertial sensors provide quantified feedback of movement disorder response to a deep brain stimulation parameter configuration. Using multidisciplinary design optimization, a minimal effective power, which is derived from tremor power and deep brain stimulation power, is acquired constituting an optimal parameter configuration.

The invention provides therapeutic methods, pharmaceutical compositions, and unit dose formulations for treating movement disorders, such as using a muscarinic acetylcholine receptor inhibitor in combination with a muscarinic acetylcholine receptor activator to treat dystonia. In some aspects, the invention provides a method of treating a movement disorder in a patient, where the method comprises administering to a patient in need thereof (i) a muscarinic acetylcholine receptor inhibitor in an amount effective to treat the movement disorder and (ii) a muscarinic acetylcholine receptor activator in an amount effective to reduce the frequency and / or magnitude of at least one side effect of the muscarinic acetylcholine receptor inhibitor, to thereby treat the movement disorder.

The utility model provides a limiting device for preventing the head from moving during examination, which relates to the technical field of medical instruments and comprises an adjusting mechanism, the adjusting mechanism comprises a nesting frame, a balance rod is arranged in the nesting frame, and an adjusting plate is arranged on the balance rod. According to the utility model, the mounting pins on the adjusting plate are nested on the examination bed, and the adjusting screw rod is rotated to carry out threaded rotation adjustment on the nesting frame, so that the distance between the expanding frame and the examination bed is adjusted until the expanding frame is adjusted to a position suitable for a patient to lie on, and then the patient lies on the examination bed; the periphery of the head of a patient is placed in the silica gel head ring, the hydraulic rods on the two sides of the silica gel head ring can be hydraulically adjusted according to the size of the head of the patient, then a worker only needs to fix the adjusting bandage in the adjusting frame in an adhesive mode, the head of the patient can be limited, and therefore the problem that the patient moves randomly in the examination process is prevented. And therefore, the practicability of the device in the actual use process is improved.

A patient's visual health can be evaluated via a virtual reality (VR) system, which includes a VR headset in electronic communication with a computing device. The computing device causes virtual environments, which can include objects, to be displayed on the VR headset. Using varying combinations of eye-tracking sensors, eye-tracking cameras, motion-tracking sensors, handheld devices, and microphones, the VR headset collects data about the patient as she tracks the objects as the objects are displayed in different positions in the virtual environments. Optionally, advanced algorithms in the computing device dynamically alter the positions of the objects and analyze the patient's eye-tracking to evaluate the patient for eye movement disorders. This dynamic evaluation can facilitate a wider scope of testing and a more detailed assessment of the patient's ocular health, as compared to traditional ocular evaluation methods.

A limb wearable neurostimulation device for treating Restless Leg Syndrome (RLS) or Periodic Limb Movement Disorder (PLMD) comprises an electrostimulation electronics unit with a printed circuit board (PCB) including a neurostimulation electrical waveform generator. The generator produces atonic motor activation (TOMAC) excitation waveform for delivery by electrodes to patient skin, configured with constant current, frequency of 1,000-5,000 Hz, zero-to-peak current amplitude of 10-50 mA. The device includes an electronics housing and a heat sink or insulating cover arranged to receive thermal conduction from PCB components and regulate thermal output of the electronics housing.

Described herein are triazalone compounds of Formula (I): and pharmaceutically acceptable salts thereof. Methods of making and using compounds of Formula (I) are also described. Compounds of Formula (I) and pharmaceutically acceptable salts thereof can be useful as adenosine receptor antagonists, for example in the treatment of diseases or conditions mediated by the adenosine receptor, such as cancer, movement disorders, or attention disorders.

The present disclosure provides: a) solid state forms of a compound having Structure (I) and Structure (II); b) crystalline forms of compounds having Structure (II); c) compounds having a Formula (III); d) compounds having a Formula (VI); e) deuterated analogs; f) pharmaceutical compositions comprising one or more of the solid state forms, crystalline forms, compounds, or deuterated analogs disclosed herein, and optionally, a pharmaceutically acceptable carrier or diluent; g) formulations comprising one or more of the solid state forms, crystalline forms, compounds, or deuterated analogs disclosed herein; h) extended release compositions comprising one or more of the solid state forms, crystalline forms, compounds, or deuterated analogs disclosed herein; i) methods of treating movement disorders by administering one or more of the solid state forms, crystalline forms, compounds, deuterated analogs, formulations, or compositions disclosed herein to a subject in need thereof; and j) methods for the preparation of one or more of the solid state forms, crystalline forms, compounds, deuterated analogs, formulations, or compositions disclosed herein.